Apparent Diffusion Coefficient Can Predict Therapy Response of Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization.
Apparent diffusion coefficient
Hepatocellular carcinoma
Magnetic resonance imaging
Transcatheter arterial chemoembolization
Treatment response
Journal
Digestive diseases (Basel, Switzerland)
ISSN: 1421-9875
Titre abrégé: Dig Dis
Pays: Switzerland
ID NLM: 8701186
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
06
2021
accepted:
14
10
2021
pubmed:
9
11
2021
medline:
8
9
2022
entrez:
8
11
2021
Statut:
ppublish
Résumé
The goal of this meta-analysis was to assess the apparent diffusion coefficient (ADC) as a pre- and posttreatment (ADC value changes [ΔADC]) predictive imaging biomarker of response to transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). Scopus database, Embase database, and MEDLINE library were scanned for connections between pre- and posttreatment ADC values of HCC and response to TACE. Six studies qualified for inclusion. The following parameters were collected: authors, publication year, study design, number of patients, drugs for TACE, mean ADC value, standard deviation, measure method, b values, and Tesla strength. The Quality Assessment of Diagnostic Studies 2 instrument was employed to check the methodological quality of each study. The meta-analysis was performed by utilizing RevMan 5.3 software. DerSimonian and Laird random-effects models with inverse-variance were used to regard heterogeneity. The mean ADC values and 95% confidence intervals were computed. Six studies (n = 271 patients with 293 HCC nodules) were included. The pretreatment mean ADC in the responder group was 1.20 × 10-3 mm2/s (0.98, 1.42) and 1.14 × 10-3 mm2/s (0.89, 1.39) in the nonresponder group. The analysis of post-TACE ΔADC revealed a threshold of ≥20% to identify treatment responders. No suitable pretreatment ADC threshold to predict therapy response or discriminate between responders and nonresponders before therapy could be discovered. ΔADC can facilitate early objective response evaluation through post-therapeutic ADC alterations ≥20%. Pretreatment ADC cannot predict response to TACE.
Identifiants
pubmed: 34749359
pii: 000520716
doi: 10.1159/000520716
pmc: PMC9501788
doi:
Types de publication
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
596-606Informations de copyright
© 2021 The Author(s). Published by S. Karger AG, Basel.
Références
J Cancer Res Clin Oncol. 2013 Apr;139(4):635-43
pubmed: 23283527
World J Gastroenterol. 2004 Oct 1;10(19):2878-82
pubmed: 15334691
Hepatology. 2003 Feb;37(2):429-42
pubmed: 12540794
Front Oncol. 2021 Aug 24;11:719480
pubmed: 34504795
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
J Comput Assist Tomogr. 2008 Sep-Oct;32(5):750-6
pubmed: 18830105
Radiology. 2013 Aug;268(2):420-30
pubmed: 23616631
J Magn Reson Imaging. 2010 Feb;31(2):348-55
pubmed: 20099348
Onco Targets Ther. 2016 Nov 14;9:7029-7037
pubmed: 27895495
Eur J Radiol. 2012 Mar;81(3):472-7
pubmed: 21296517
AJR Am J Roentgenol. 2003 Sep;181(3):708-10
pubmed: 12933464
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Ann Oncol. 2013 Apr;24(4):965-73
pubmed: 23223331
BMC Med Res Methodol. 2006 Jul 12;6:31
pubmed: 16836745
AJR Am J Roentgenol. 2009 Oct;193(4):1044-52
pubmed: 19770328
Liver Cancer. 2015 Mar;4(2):106-14
pubmed: 26697413
Ann Intern Med. 2008 Dec 16;149(12):889-97
pubmed: 19075208
Radiology. 2014 Mar;270(3):747-57
pubmed: 24475816
AJR Am J Roentgenol. 2007 Jun;188(6):1622-35
pubmed: 17515386
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):546-553
pubmed: 28011045
Magn Reson Med. 2009 Apr;61(4):828-33
pubmed: 19205020
J Magn Reson Imaging. 2008 Apr;27(4):834-9
pubmed: 18383261
J Vasc Interv Radiol. 2006 Jul;17(7):1195-200
pubmed: 16868174
Semin Liver Dis. 2005;25(2):181-200
pubmed: 15918147
Radiology. 2006 May;239(2):448-56
pubmed: 16569781
Abdom Imaging. 2013 Dec;38(6):1286-99
pubmed: 23807705
Dig Dis Sci. 2020 Aug;65(8):2433-2441
pubmed: 31732907
HPB (Oxford). 2009 Nov;11(7):541-50
pubmed: 20495705
J Magn Reson Imaging. 2012 Apr;35(4):745-63
pubmed: 22434697
Ann Surg. 2003 Nov;238(5):703-10
pubmed: 14578733
AJR Am J Roentgenol. 2018 Nov;211(5):W205-W216
pubmed: 30240291
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Eur Radiol. 2011 Feb;21(2):265-73
pubmed: 20730540
Med Sci Monit. 2011 Apr;17(4):CR189-95
pubmed: 21455104
Radiology. 2009 Feb;250(2):466-73
pubmed: 19188315
J Vasc Interv Radiol. 2006 Mar;17(3):505-12
pubmed: 16567675
AJR Am J Roentgenol. 2007 Oct;189(4):799-806
pubmed: 17885048
World J Hepatol. 2016 Mar 28;8(9):421-38
pubmed: 27028578
Eur J Radiol. 2013 Apr;82(4):577-82
pubmed: 23246330
Dis Esophagus. 2019 Apr 1;32(4):
pubmed: 30010733
Acta Radiol. 2008 Jun;49(5):523-9
pubmed: 18568538
Front Oncol. 2020 Nov 19;10:600233
pubmed: 33330098
Gastroenterology. 2004 Nov;127(5 Suppl 1):S248-60
pubmed: 15508091
Korean J Radiol. 2009 Sep-Oct;10(5):425-34
pubmed: 19721826
Abdom Imaging. 2002 Mar-Apr;27(2):168-79
pubmed: 11847576
Korean J Radiol. 2019 Apr;20(4):649-661
pubmed: 30887747
Liver Transpl. 2004 Feb;10(2 Suppl 1):S39-45
pubmed: 14762838
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Vasc Interv Radiol. 2012 Feb;23(2):241-7
pubmed: 22019180
Cardiovasc Intervent Radiol. 2010 Jun;33(3):541-51
pubmed: 19937027
J Cancer. 2020 Feb 10;11(8):2339-2347
pubmed: 32127960
Liver Cancer. 2012 Nov;1(3-4):144-58
pubmed: 24159579
Anticancer Res. 2021 Mar;41(3):1163-1170
pubmed: 33788707
Radiology. 1996 Jan;198(1):33-40
pubmed: 8539401
J Vasc Interv Radiol. 2015 Dec;26(12):1777-86
pubmed: 26603497
Lancet. 2002 May 18;359(9319):1734-9
pubmed: 12049862
Cancer J. 2009 Nov-Dec;15(6):526-32
pubmed: 20010173
Cancer. 2002 Mar 15;94(6):1747-52
pubmed: 11920537
J Magn Reson Imaging. 2005 Jul;22(1):80-5
pubmed: 15971188
Clin Gastroenterol Hepatol. 2007 Sep;5(9):1100-8
pubmed: 17627902
J Magn Reson Imaging. 2008 May;27(5):1069-76
pubmed: 18407540
J Surg Oncol. 2010 May 1;101(6):476-80
pubmed: 20213741
Cardiovasc Intervent Radiol. 2010 Feb;33(1):41-52
pubmed: 19908093
Breast Cancer Res Treat. 2012 Aug;135(1):17-28
pubmed: 22476850
Gastroenterology. 2011 Aug;141(2):526-35, 535.e1-2
pubmed: 21664356
Oncotarget. 2017 May 10;8(35):59492-59499
pubmed: 28938652
J Magn Reson Imaging. 2015 Oct;42(4):981-9
pubmed: 25683022
Magn Reson Med. 2009 Dec;62(6):1414-22
pubmed: 19785014
Sci Rep. 2019 Oct 2;9(1):14157
pubmed: 31578433
Oncol Rep. 2010 Sep;24(3):727-32
pubmed: 20664980